InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
InflaRx (Nasdaq: IFRX) announced a late-breaking oral presentation of Phase 3 vilobelimab results in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting in Denver, March 27-31, 2026.
The oral session is scheduled for March 28, 2026, 2:24-2:36 PM MT, presenter Benjamin Kaffenberger, MD. The company also highlights its izicopan program and anti-C5a/C5aR platform.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – IFRX
-3.64%3.0x vol
8 alerts
-3.64%Session close to close
+7.0%Peak Tracked
-19.0%Trough Tracked
$63.65MMarket Cap
3.0xRel. Volume
In the Mar 18 session, IFRX declined 3.64%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +7.0% during that session.
Argus tracked a trough of -19.0% from its starting point during tracking.
Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Trading volume was elevated at 3.0x the daily average, suggesting increased selling activity.
This announcement highlights a late-breaking oral presentation of Phase 3 vilobelimab data in pyoder...
Analysis
This announcement highlights a late-breaking oral presentation of Phase 3 vilobelimab data in pyoderma gangrenosum at the AAD 2026 meeting, underscoring ongoing scientific interest in the PG program. It follows earlier updates where the PG trial was stopped for futility and detailed analyses were later provided. In parallel, InflaRx has emphasized its oral C5aR inhibitor INF904 in CSU and HS. Investors may watch for how these PG data are received at AAD and for further INF904 development milestones.
Key Figures
Phase 3 trial:Phase 3Oral program stages:Phase 1 and Phase 2aAAD 2026 dates:March 27–31, 2026+2 more
5 metrics
Phase 3 trialPhase 3Vilobelimab in ulcerative pyoderma gangrenosum (PG)
Oral program stagesPhase 1 and Phase 2aIzicopan (INF904) development history
AAD 2026 datesMarch 27–31, 2026American Academy of Dermatology Annual Meeting schedule
Late-breaker time2:24–2:36 PM MTVilobelimab Phase 3 PG oral presentation slot on March 28, 2026
GOHIBIC (vilobelimab) selected for BARDA-sponsored ARDS Phase 2 study.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Clinical trial catalysts have often produced strong moves, with notably large reactions both positive (INF904 topline) and negative (vilobelimab PG futility).
Recent Company History
Over the past year, InflaRx has reported multiple clinical milestones across vilobelimab and INF904. A May 28, 2025 interim analysis led to stopping the vilobelimab PG Phase 3 for futility, while a Nov 7, 2025 update flagged upcoming Phase 2a INF904 topline data. Earlier, a Dec 20, 2024 release marked first dosing in an INF904 Phase 2a basket study, and a Jun 24, 2024 announcement highlighted BARDA’s selection of GOHIBIC for an ARDS trial. Today’s AAD late-breaker continues this PG data narrative.
Key Terms
pyoderma gangrenosum, c5a, c5ar, monoclonal antibody, +4 more
8 terms
pyoderma gangrenosummedical
"Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter"
A rare, painful inflammatory skin disorder that produces rapidly expanding ulcers and deep wounds, often following minor injury or linked to immune-system abnormalities; it can be hard to heal and may recur. It matters to investors because it represents a clear unmet medical need and a distinct clinical and regulatory challenge—new effective therapies can create commercial opportunity, affect trial outcomes and safety profiles, and influence valuation of companies developing treatments.
c5amedical
"targeting the role of C5a/C5aR inhibition in other chronic immuno-inflammatory diseases."
C5a is a small protein produced by the immune system that acts like an alarm bell, signaling and attracting immune cells to sites of infection or injury and triggering inflammation. Investors care because excessive or uncontrolled C5a activity is linked to many inflammatory and autoimmune diseases, making it a common target for drugs and diagnostics; treatments that block or measure C5a can affect clinical outcomes, regulatory approval prospects, and commercial value in biotech and pharmaceutical portfolios.
c5armedical
"targeting the role of C5a/C5aR inhibition in other chronic immuno-inflammatory diseases."
C5aR is a protein on the surface of immune cells that senses and responds to a small immune signaling molecule called C5a; when activated it acts like a doorbell that calls immune cells and ramps up inflammation. It matters to investors because drugs that block or modulate this receptor can reduce harmful inflammation in diseases, so clinical trial results, approvals, or setbacks for C5aR-targeting therapies can materially affect a biotech’s value and market prospects.
monoclonal antibodymedical
"vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
pharmacokineticsmedical
"which has shown promising PK/PD characteristics as well as therapeutic potential"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
pk/pdmedical
"which has shown promising PK/PD characteristics as well as therapeutic potential"
PK/PD stands for pharmacokinetics and pharmacodynamics: PK describes how a drug moves through the body — how it is absorbed, distributed, broken down and eliminated — while PD describes the drug’s effects on the body and how those effects change with dose. For investors, strong PK/PD data help predict whether a drug can be dosed safely and effectively, shape clinical trial success, regulatory approval chances and commercial potential, much like knowing both delivery speed and the strength of a message before choosing a shipping method.
hidradenitis suppurativamedical
"The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS)."
A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.
immuno-inflammatorymedical
"role of C5a/C5aR inhibition in other chronic immuno-inflammatory diseases."
Immuno-inflammatory describes processes in which the immune system causes or controls inflammation in the body — a coordinated response that can protect against infection but also drive chronic illness when overactive. Investors care because many drugs, devices and diagnostics target these pathways; success or failure in clinical trials, approvals or reimbursements for immuno-inflammatory therapies can quickly change a company’s revenue outlook, valuation and market opportunity, like fixing a faulty fire alarm that either prevents disaster or keeps dousing the house.
JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The meeting will be held March 27-31, 2026, in Denver, CO.
Camilla Chong, MD, Chief Medical Officer of InflaRx, said: “It is an honor that our Phase 3 study data for vilobelimab in pyoderma gangrenosum (PG) have been selected for a late-breaking oral presentation at AAD. We look forward to engaging with the dermatology community on these critical findings in PG and our development program targeting the role of C5a/C5aR inhibition in other chronic immuno-inflammatory diseases.”
AAD 2026 Late-Breaking Presentation Details Title: Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial
Session Type: Oral presentation Presenter: Benjamin Kaffenberger, MD Time: March 28, 2026, 2:24-2:36 PM MT Location: Bellco Theatre 3
About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
InflaRx N.V.
MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752
FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
What did InflaRx (IFRX) announce about vilobelimab Phase 3 data on March 18, 2026?
InflaRx announced a late-breaking oral presentation of Phase 3 vilobelimab results at AAD 2026. According to InflaRx, the data will be discussed during a March 28 oral session focused on ulcerative pyoderma gangrenosum.
When and where will InflaRx (IFRX) present vilobelimab Phase 3 results at AAD 2026?
The presentation is scheduled for March 28, 2026, 2:24-2:36 PM MT in Denver, CO. According to InflaRx, it will be an oral late-breaking session at the AAD Annual Meeting.
Who will present InflaRx's (IFRX) vilobelimab Phase 3 findings at AAD 2026?
Benjamin Kaffenberger, MD, will present the oral late-breaking session on March 28, 2026. According to InflaRx, Dr. Kaffenberger will discuss results from the multicenter, randomized, placebo-controlled trial.
What is the focus of the vilobelimab Phase 3 presentation by InflaRx (IFRX)?
The presentation focuses on vilobelimab treatment for ulcerative pyoderma gangrenosum from a Phase 3 randomized, placebo-controlled trial. According to InflaRx, the session will review efficacy and tolerability data.
How does this AAD presentation relate to InflaRx's (IFRX) broader pipeline?
The presentation highlights InflaRx's anti-C5a/C5aR therapeutic approach and vilobelimab clinical progress. According to InflaRx, it complements development of izicopan and other C5a-targeting programs.
Can investors attend or view InflaRx's (IFRX) vilobelimab presentation at AAD 2026?
Investors can attend the AAD Annual Meeting in Denver to hear the oral session on March 28, 2026. According to InflaRx, details on access and timing are provided through the meeting program and company communications.
